<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04831151</url>
  </required_header>
  <id_info>
    <org_study_id>2021/28</org_study_id>
    <nct_id>NCT04831151</nct_id>
  </id_info>
  <brief_title>The Effect of Polycystic Ovary Syndrome Treatment on Metabolomics</brief_title>
  <official_title>The Effect of Two Combined Oral Contraceptives Containing Cyproterone Acetate or Drospirenone on Blood Metabolomics in Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inonu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inonu University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the effect of the treatment of polycystic ovary&#xD;
      syndrome with two different oral contraceptives that contain cyproterone acetate and&#xD;
      drospirenone&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polycystic ovary syndrome (PCOS), is the most common endocrinological disorder that affects&#xD;
      the reproductive aged women. In addition to causing problems such as menstrual irregularity,&#xD;
      hirsutism, acne, it is also an important health problem that can cause infertility, insulin&#xD;
      resistance, impaired glucose metabolism, diabetes, high blood pressure, heart disease,&#xD;
      dyslipidemia in advanced ages. Diagnostic criteria also vary widely in these patients. These&#xD;
      patients are often overweight or obese, and abdominal adiposity is common in these patients.&#xD;
      The patients also suffer from insulin resistance and hyperinsulinemia in this syndrome. All&#xD;
      of this is probably the result of a vicious cycle that starts in the antenatal period.&#xD;
      Combined oral contraceptives (COCs), are the first-choice treatment option for many patients&#xD;
      by improving both menstrual irregularity, hyperandrogenism, and insulin resistance through&#xD;
      sex hormone binding globulin (SHBG). They reduce the risk of endometrial hyperplasia and&#xD;
      endometrial cancer by providing regular menstruation.&#xD;
&#xD;
      Nowadays, the use of metabolomics is increasing in understanding the pathophysiology of&#xD;
      diseases. Metabolomics technology examines low molecular weight substrates used in&#xD;
      intracellular enzymatic reactions, intermediates and end products resulting from these&#xD;
      reactions. Metabolomic examinations are gaining momentum in terms of understanding the&#xD;
      pathophysiology of diseases, especially endometrial cancer and ovarian cancer, in the field&#xD;
      of Obstetrics and Gynecology. Metabolomics continue to be investigated in understanding the&#xD;
      pathophysiology of PCOS, but there are not enough studies yet on the effects of treatment on&#xD;
      the disease in terms of metabolomics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolomics</measure>
    <time_frame>3 months</time_frame>
    <description>measured by H1 nuclear magnetic resonance spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hirsutism score</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by modified Ferriman Gallwey scoring system ranges between 0-36 points. Higher scores means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting serum insulin levels</measure>
    <time_frame>3 months</time_frame>
    <description>measured on the 3rd day of menstrual cycle, before before 10 am, after 8-hour-night fasting. The lower levels means better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>low density lipoprotein</measure>
    <time_frame>3 months</time_frame>
    <description>measured on the 3rd day of menstrual cycle, before before 10 am, after 8-hour-night fasting. The lower levels means better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>body mass index</measure>
    <time_frame>3 months</time_frame>
    <description>weight and height will be combined to report BMI in kg/m^2. The lower index means better results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical findings</measure>
    <time_frame>3 months</time_frame>
    <description>Rising the number of participants with menstrual periods shorter than 35 days means better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Drospirenone group: 0,03 mg ethinylestradiol + 3 mg drospirenone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>generic name:yasmin dosage form:oral dosage: 0,03 mg ethinylestradiol + 3 mg drospirenone frequency: once a day duration: 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cyproterone acetate group: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>generic name:diane 35 dosage form:oral dosage: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate frequency: once a day duration: 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Yasmin</intervention_name>
    <description>Yasmin: 0,03 mg ethinylestradiol + 3 mg drospirenone</description>
    <arm_group_label>Drospirenone group: 0,03 mg ethinylestradiol + 3 mg drospirenone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diane-35</intervention_name>
    <description>Diane 35: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate</description>
    <arm_group_label>cyproterone acetate group: 0,035 mg ethinylestradiol + 2 mg cyproterone acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who are diagnosed with polycystic ovary syndrome according to Rotterdam&#xD;
             criteria and who do not have any additional chronic systemic disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The presence of any diseases that cause hormonal disorders and any chronic systemic&#xD;
             diseases, the patients who are already under any treatment for polycystic ovary&#xD;
             syndrome&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Senem Arda Düz, Asisstant professor</last_name>
    <phone>+905332776401</phone>
    <email>senem_arda@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inonu University</name>
      <address>
        <city>Malatya</city>
        <zip>44280</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Senem Arda Düz, Assistant Professor</last_name>
      <phone>+905332776401</phone>
      <email>senem_arda@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Erdinç Sarıdoğan, Assistant professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Görkem Tuncay, Associate professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Abdullah Karaer, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2021</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inonu University</investigator_affiliation>
    <investigator_full_name>Senem Arda Düz</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <keyword>hirsutism</keyword>
  <keyword>combined oral contraceptives</keyword>
  <keyword>amenorrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyproterone acetate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

